Hyperthermic isolated limb perfusion for extremity soft tissue sarcomas: Systematic review of clinical efficacy and quality assessment of reported trials

Trabulsi, Nora; Patakfalvi, Laura; Nassif, Mohammed; Turcotte, Robert; Nichols, Anthony C.; Meguerditchian, Ari-Nareg

doi:10.1002/jso.23200

Cited by 26 publications

(14 citation statements)

References 50 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…General feasibility of local CTHT has also been shown in other entities such as refractory or recurrent non-testicular germ cell carcinomas, recurrent or persistent ovarian cancer, breast carcinoma, or peritoneal carcinomatosis in several phase II studies (140–143). As alternative to regional HT, hyperthermic isolated limb perfusion has been established for the treatment of STS and unresectable melanomas showing favorable results (144, 145). In summary, the few existing randomized trials suggest substantial benefit by adding HT to CT. More randomized trials are necessary to broaden the spectrum of CTHT.…”

Section: Clinical Evidence Of Combined Thermoradiotherapymentioning

confidence: 99%

Integrating Hyperthermia into Modern Radiation Oncology: What Evidence Is Necessary?

2017

View full text Add to dashboard Cite

Hyperthermia (HT) is one of the hot topics that have been discussed over decades. However, it never made its way into primetime. The basic biological rationale of heat to enhance the effect of radiation, chemotherapeutic agents, and immunotherapy is evident. Preclinical work has confirmed this effect. HT may trigger changes in perfusion and oxygenation as well as inhibition of DNA repair mechanisms. Moreover, there is evidence for immune stimulation and the induction of systemic immune responses. Despite the increasing number of solid clinical studies, only few centers have included this adjuvant treatment into their repertoire. Over the years, abundant prospective and randomized clinical data have emerged demonstrating a clear benefit of combined HT and radiotherapy for multiple entities such as superficial breast cancer recurrences, cervix carcinoma, or cancers of the head and neck. Regarding less investigated indications, the existing data are promising and more clinical trials are currently recruiting patients. How do we proceed from here? Preclinical evidence is present. Multiple indications benefit from additional HT in the clinical setting. This article summarizes the present evidence and develops ideas for future research.

show abstract

Section: Clinical Evidence Of Combined Thermoradiotherapymentioning

confidence: 99%

Integrating Hyperthermia into Modern Radiation Oncology: What Evidence Is Necessary?

2017

View full text Add to dashboard Cite

show abstract

“…Therefore well designed prospective randomized trials are still warranted to validate these findings. (92) Bladder Cancer…”

Section: Randomized Trials Of Chemotherapy and Hyperthermia Sarcomamentioning

confidence: 99%

Hyperthermia, Radiation and Chemotherapy: The Role of Heat in Multidisciplinary Cancer Care

Hurwitz

Stauffer

2014

Seminars in Oncology

118

104

View full text Add to dashboard Cite

“…However, these molecules are not employed to boost tumor-targeting immune responses, but rather as immunoreconstituting (G-CSF, GM-CSF) [36][37][38][39][40][41][42][43] or oncotoxic (TNF) factors. [44][45][46][47][48][49][50][51][52][53][54][55] Importantly, cytokines can cause relatively severe adverse effects (especially upon systemic administration), which de facto reflect their robust immunostimulatory activity and/or their biological pleiotropism. In particular, cytokines can (1) trigger an acute, potentially lethal systemic response that involves the release of pyrogenic and cytotoxic mediators (including additional cytokines) into the bloodstream; 56-60 (2) establish or perpetuate foci of chronic inflammation that may sustain oncogenesis or tumor progression; [61][62][63] or (3) promote proliferation among otherwise non-proliferating cells, thereby promoting the fixation of potentially oncogenic genetic or epigenetic defects.…”

Section: Introductionmentioning

confidence: 99%

Trial Watch—Immunostimulation with cytokines in cancer therapy

Vacchelli¹,

Aranda

Bloy³

et al. 2015

OncoImmunology

View full text Add to dashboard Cite

During the past decade, great efforts have been dedicated to the development of clinically relevant interventions that would trigger potent (and hence potentially curative) anticancer immune responses. Indeed, developing neoplasms normally establish local and systemic immunosuppressive networks that inhibit tumor-targeting immune effector cells, be them natural or elicited by (immuno)therapy. One possible approach to boost anticancer immunity consists in the (generally systemic) administration of recombinant immunostimulatory cytokines. In a limited number of oncological indications, immunostimulatory cytokines mediate clinical activity as standalone immunotherapeutic interventions. Most often, however, immunostimulatory cytokines are employed as immunological adjuvants, i.e., to unleash the immunogenic potential of other immunotherapeutic agents, like tumor-targeting vaccines and checkpoint blockers. Here, we discuss recent preclinical and clinical advances in the use of some cytokines as immunostimulatory agents in oncological indications.

show abstract

Hyperthermic isolated limb perfusion for extremity soft tissue sarcomas: Systematic review of clinical efficacy and quality assessment of reported trials

Abstract: HILP seems effective in treating advanced extremity STS. However, poor publication quality hinders results validity. Technical and methodological standardization, well-designed, multi-institutional trials are warranted.

Cited by 26 publications

References 50 publications

Integrating Hyperthermia into Modern Radiation Oncology: What Evidence Is Necessary?

Integrating Hyperthermia into Modern Radiation Oncology: What Evidence Is Necessary?

Hyperthermia, Radiation and Chemotherapy: The Role of Heat in Multidisciplinary Cancer Care

Trial Watch—Immunostimulation with cytokines in cancer therapy

Contact Info

Product

Resources

About